Back to Search Start Over

Plasma-based COVID-19 treatments in low- and middle-income nations pose a high risk of an HIV epidemic.

Authors :
Ferreira LMR
Mostajo-Radji MA
Source :
NPJ vaccines [NPJ Vaccines] 2020 Jul 06; Vol. 5, pp. 58. Date of Electronic Publication: 2020 Jul 06 (Print Publication: 2020).
Publication Year :
2020

Abstract

Convalescent plasma therapy holds promise as a transient treatment for COVID-19. Yet, blood products are important sources of HIV infection in low- and middle-income nations. Great care must be taken to prevent plasma therapy from fueling HIV epidemics in the developing world.<br />Competing Interests: Competing interestsL.M.R.F. holds patents on cell-based gene therapy methods for HIV treatment. M.A.M.-R. is the Bolivian Science, Technology and Innovation Ambassador and leads the Bolivian COVID-19 response team. The authors declare no other conflict of interest.<br /> (© The Author(s) 2020.)

Details

Language :
English
ISSN :
2059-0105
Volume :
5
Database :
MEDLINE
Journal :
NPJ vaccines
Publication Type :
Academic Journal
Accession number :
32655899
Full Text :
https://doi.org/10.1038/s41541-020-0209-2